Guide
Setting Up a Clinical-Research, CRO or Trial-Support Company in the UAE
Published
The short answer
Health research in the UAE sits under two layers: the federal Ministry of Health and Prevention (MOHAP), and the health authority of the emirate where the work happens — the Dubai Health Authority (DHA) or the Department of Health in Abu Dhabi. Before a company can describe itself as running trials, the relevant health authority and an ethics committee need to have reviewed the protocol, not only a commercial licence. The question that most often decides the route is which part of the trial the UAE entity actually performs — full sponsor-side delivery, site management, data and biostatistics, or technology and recruitment support — because each carries a different approval burden.
Which of the four models you are actually building
A trial-support business is rarely one thing. Four distinct models cover most launches, each putting a different party in front of the health authority:
- Full-service CRO managing a sponsor's programme end to end, including sites, monitoring and reporting.
- Site-management organisation supporting investigator sites without holding the full sponsor relationship.
- Data-management and biostatistics provider working on trial data without touching participants directly.
- Trial technology or recruitment platform providing software or patient-finding services to sponsors and sites.
The further down this list, the more likely the UAE company is a vendor to a regulated party rather than the regulated party itself — but that is a conclusion to test, not assume. A full-service CRO signing directly with an international sponsor must show who is accountable for safety reporting and data integrity on the ground. A data-management provider still needs a contract stating, in writing, that it makes no clinical decisions. Fix which model applies before naming a commercial activity, as a founder would for a genomic-testing, genetic-laboratory or biobank company.
The regulatory perimeter: who decides, and on what
MOHAP sets the federal position on the use of human subjects in biomedical research; the emirate health authority where the study runs — DHA in Dubai, the Department of Health in Abu Dhabi — administers research-ethics review and day-to-day oversight of sites, investigators and data handling. A company that only coordinates, recruits or processes data for studies run elsewhere may sit outside direct health-authority licensing, but ethics and safety-reporting obligations usually still attach to whoever touches participants, samples or identifiable data.
Treat "does this health authority need to approve our protocol before anyone is enrolled" as the first gate, not something a commercial registration answers by default. Record the current conclusion, the source it rests on, and the fact that would change it — a new site, sponsor type or data flow. Confirm the position directly with MOHAP and the relevant emirate authority before filing; this guide sets out the shape of the question, not a ruling on it.
What the health authority and sponsor actually expect in writing
Before a UAE entity can credibly claim it runs or supports trials, it needs documents that show, not assert, how responsibility is allocated:
- A sponsor, investigator, institution and CRO delegation log naming who owns each regulated task.
- A protocol and informed-consent process consistent with the study's ethics approval.
- A safety-reporting line that says who receives, assesses and escalates adverse events, and by when.
- A data-handling map showing where participant data, samples and trial master files are stored and who can access them.
Sponsors increasingly ask for this evidence before signing. A business plan describing services sold, without this allocation, stalls at due diligence even where the commercial licence is valid.
How money moves, and what a bank will ask
CRO revenue is usually milestone-based: a sponsor pays on enrolment targets, data milestones or study close-out, and the UAE entity often passes a share straight through to sites, laboratories or specialist vendors. International sponsors paying into a UAE account, and payouts to sites and consultants abroad, both draw bank scrutiny of the purpose behind each flow.
Prepare the banking conversation with the same specificity as the regulatory one: which sponsors pay in, against which contract milestones, and which parties are paid out and why. A pass-through fee structure left undocumented in the contract looks, to a bank, indistinguishable from an unexplained transfer. Build this evidence alongside banking readiness rather than after an account is declined.
Ownership, funding and the roles that must be filled
Many CRO groups in the UAE are subsidiaries of, or joint ventures with, sponsors, pharmaceutical companies or international research networks. Where ownership includes foreign funds, holding structures or co-investors, the bank and the authority both want to see where the money funding the UAE entity came from, not only who signed the shareholder register. Where the chain is layered, plan the structure as regulated and complex ownership, not as an afterthought to incorporation.
On the operating side, name who in the UAE entity is accountable for quality systems, safety reporting and responding to an authority inspection. A CRO that relies entirely on a parent company's staff abroad for these functions will struggle to show the substance a health authority and a sponsor both expect from a UAE-based operation.
What commonly goes wrong
- Marketing full-service CRO capability before the quality system and delegation log exist to support it.
- Treating commercial registration as if it were study or ethics approval.
- Recruiting participants, or contacting sites, before ethics and site permissions are confirmed.
- Leaving it unclear who owns safety-reporting obligations when a CRO works through subcontractors.
- Comparing formation prices across jurisdictions before testing whether the health-authority position is even the same.
Most of these share a root cause: a vague commercial activity leads to a vague contract, and a vague contract is what a bank or a sponsor's due-diligence team eventually rejects. Fix the model and the delegation log first.
